Wire · opportunities
Otsuka's ADHD approval opens up new drug class with $615M opportunity
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
Otsuka's centanafadine (Simtriyo) becomes the first norepinephrine-dopamine-serotonin reuptake inhibitor approved for ADHD, with peak sales forecast at $615m. The drug launches later this year pending DEA scheduling and carries boxed warnings for suicidal ideation and abuse potential.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
If you're building ADHD diagnostics, patient management tools, or adherence platforms, the non-stimulant category just proved out as a real alternative—and it now has a $615m anchor drug to build around. Stimulant supply constraints and abuse concerns just gave a non-stimulant its widest opening yet.
◆ Coverage
1 source · 27 Jul 2026
◆ Related on Wire
◆ Topics